Equities analysts forecast that Proteon Therapeutics, Inc. (NASDAQ:PRTO) will announce ($0.45) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Proteon Therapeutics’ earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.40). Proteon Therapeutics posted earnings per share of ($0.48) in the same quarter last year, which indicates a positive year-over-year growth rate of 6.2%. The company is expected to announce its next earnings report before the market opens on Monday, August 14th.
On average, analysts expect that Proteon Therapeutics will report full year earnings of ($1.68) per share for the current year, with EPS estimates ranging from ($1.95) to ($1.47). For the next fiscal year, analysts expect that the firm will report earnings of ($1.51) per share, with EPS estimates ranging from ($1.87) to ($1.00). Zacks’ EPS calculations are a mean average based on a survey of research firms that that provide coverage for Proteon Therapeutics.
Proteon Therapeutics (NASDAQ:PRTO) last issued its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.39) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.04.
PRTO has been the subject of several recent research reports. Zacks Investment Research downgraded Proteon Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Maxim Group set a $6.00 price objective on Proteon Therapeutics and gave the company a “buy” rating in a report on Thursday, May 4th. Finally, HC Wainwright set a $3.00 price objective on Proteon Therapeutics and gave the company a “hold” rating in a report on Saturday, May 13th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $8.14.
TRADEMARK VIOLATION WARNING: “-$0.45 EPS Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://stocknewstimes.com/2017/08/07/0-45-eps-expected-for-proteon-therapeutics-inc-prto-this-quarter.html.
Shares of Proteon Therapeutics (NASDAQ PRTO) traded up 8.00% on Friday, hitting $1.35. 24,013 shares of the company traded hands. The firm’s 50-day moving average is $1.37 and its 200 day moving average is $1.57. Proteon Therapeutics has a 1-year low of $1.10 and a 1-year high of $11.45. The firm’s market capitalization is $22.64 million.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Get a free copy of the Zacks research report on Proteon Therapeutics (PRTO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
